Literature DB >> 18088158

Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination.

Roberto Pradas-Velasco1, Fernando Antoñanzas-Villar, María Puy Martínez-Zárate.   

Abstract

OBJECTIVE: To evaluate the economic efficiency of influenza vaccination using both dynamic and static modelling approaches.
SETTING: The Spanish National Health System. DESIGN AND METHODS: We modelled the progress of an influenza epidemic in Spain according to the epidemiological pattern of susceptible-->infective-->resistant, employing a non-linear system of ordinary differential equations that enables the measurement of epidemiological effects of an anti-influenza vaccination. We used a decision tree to represent the repercussion on healthcare resources use and on financial resources. The same analyses were conducted using a static approach, and the results were compared. Healthcare costs were valued in euro, year 2005 values.
RESULTS: For the base case, the impact of the healthcare intervention (vaccination) was not efficient from the perspective of the healthcare payer when using a static approach (return rate 0.28 per euro invested in vaccination). Nevertheless, it was efficient when employing a dynamic approach (return rate 1.22 per euro). Furthermore, a considerable freeing of healthcare resources would have been produced over the entire influenza season.
CONCLUSIONS: The indirect effect of vaccination on the non-vaccinated individuals (the 'herd immunity effect') can be greater than the direct effect on individuals vaccinated. This implies that the herd immunity effect needs to be taken into consideration in the economic evaluations of prophylactic measures employed against infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18088158     DOI: 10.2165/00019053-200826010-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

Authors:  K L Nichol
Journal:  Arch Intern Med       Date:  2001-03-12

2.  Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.

Authors:  P A Muennig; K Khan
Journal:  Clin Infect Dis       Date:  2001-10-22       Impact factor: 9.079

3.  A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.

Authors:  Roben Das Gupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Exploring cross-protection between influenza strains by an epidemiological model.

Authors:  Audrey Lavenu; Alain-Jacques Valleron; Fabrice Carrat
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

5.  [Flu vaccination status of primary care staff].

Authors:  M A Pastor Climent; H Schwarz Chávarri; V Pedrera Carbonell; M Pascual de la Torre
Journal:  Aten Primaria       Date:  2004-02-28       Impact factor: 1.137

6.  Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.

Authors:  Beate Sander; Frederick G Hayden; Marlene Gyldmark; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

Authors:  James Ryan; York Zoellner; Birgit Gradl; Bram Palache; Jeroen Medema
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

Review 8.  [Influenza surveillance. New solutions to an old problem].

Authors:  Salvador de Mateo; Amparo Larrauri; Carmen Mesonero
Journal:  Gac Sanit       Date:  2006 Jan-Feb       Impact factor: 2.139

9.  Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.

Authors:  Caroline L Trotter; W John Edmunds
Journal:  Med Decis Making       Date:  2006 Jan-Feb       Impact factor: 2.583

10.  [Analysis of a economic model of a populational influenza immunization strategy in healthy employees].

Authors:  Jesus Martín Fernández
Journal:  Rev Esp Salud Publica       Date:  2006 May-Jun
View more
  15 in total

1.  Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs.

Authors:  Yoko Ibuka; A David Paltiel; Alison P Galvani
Journal:  Med Decis Making       Date:  2012-04-03       Impact factor: 2.583

2.  Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.

Authors:  Lidia Brydak; Julie Roiz; Pascaline Faivre; Camille Reygrobellet
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

3.  Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.

Authors:  Mohamed A Kamal; Patrick F Smith; Nathorn Chaiyakunapruk; David B C Wu; Chayanin Pratoomsoot; Kenneth K C Lee; Huey Yi Chong; Richard E Nelson; Keith Nieforth; Georgina Dall; Stephen Toovey; David C M Kong; Aaron Kamauu; Carl M Kirkpatrick; Craig R Rayner
Journal:  Br J Clin Pharmacol       Date:  2017-02-20       Impact factor: 4.335

4.  Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines.

Authors:  Jamison Pike; Andrew J Leidner; Harrell Chesson; Charles Stoecker; Scott D Grosse
Journal:  Appl Health Econ Health Policy       Date:  2022-02-09       Impact factor: 3.686

5.  Economic Evaluations of New Antibiotics: The High Potential Value of Reducing Healthcare Transmission Through Decolonization.

Authors:  Damon J A Toth; Matthew H Samore; Richard E Nelson
Journal:  Clin Infect Dis       Date:  2021-01-29       Impact factor: 9.079

6.  Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.

Authors:  D B C Wu; N Chaiyakunapruk; C Pratoomsoot; K K C Lee; H Y Chong; R E Nelson; P F Smith; C M Kirkpatrick; M A Kamal; K Nieforth; G Dall; S Toovey; D C M Kong; A Kamauu; C R Rayner
Journal:  Epidemiol Infect       Date:  2018-02-15       Impact factor: 4.434

7.  Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Authors:  Bernhard Ultsch; Oliver Damm; Philippe Beutels; Joke Bilcke; Bernd Brüggenjürgen; Andreas Gerber-Grote; Wolfgang Greiner; Germaine Hanquet; Raymond Hutubessy; Mark Jit; Mirjam Knol; Rüdiger von Kries; Alexander Kuhlmann; Daniel Levy-Bruhl; Matthias Perleth; Maarten Postma; Heini Salo; Uwe Siebert; Jürgen Wasem; Ole Wichmann
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

8.  An approximation of herd effect due to vaccinating children against seasonal influenza - a potential solution to the incorporation of indirect effects into static models.

Authors:  Ilse Van Vlaenderen; Laure-Anne Van Bellinghen; Genevieve Meier; Barbara Poulsen Nautrup
Journal:  BMC Infect Dis       Date:  2013-01-22       Impact factor: 3.090

9.  Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study.

Authors:  Marc Baguelin; Anton Camacho; Stefan Flasche; W John Edmunds
Journal:  BMC Med       Date:  2015-10-13       Impact factor: 8.775

10.  Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.

Authors:  Amos García; Raúl Ortiz de Lejarazu; Jordi Reina; Daniel Callejo; Jesús Cuervo; Raúl Morano Larragueta
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.